Curative Effect and Adverse Reactions of Gemzar(Gemcitabine) Combined with Cisplatin for the Treament of Late Nonsmall-cell Lung Cancer

OBJECTIVE:To observe curative effect and adverse reactions of gemzar (gemcitabine) combined with cisplatin for the treatment of late NSCLC for 3 and 4 weeks. METHODS: The patients with late NSCLC verificated by pathology and cytology were chosen, who didn’t undertake chemotherapy and radiotherapy in the past. They were found to have clinically measurable focus (based on WHO standard ), ECOG sore ranged from 0 to 2 and heptic and renal function were basically normal. They were all given gemzar combined with cisplatin. Curative effect and adverse reactions were evaluated by WHO standard. Their survival time was followed up. RESULTS : 33 cases were elected into the study group. Of those, curative effect in 29 cases could be evaluated. 14 of 29 cases were PR(48.3%) ; 8 cases were SD(27.6%) and 7 cases were PD(24.1%). Neutral survival time was 9.1 months, ranging from 2.7 to 19.1 months. The main adverse reactions were hematologic toxicity. The manifestations were : WBC, neutrophile granulocyte, blood platelet and hemoglobin all decreased, then was digestive canal symptoms. CONCLUSION: Gemzar is an effective antitumor drug, which combines with cisplatin is one of the first-line chemotherapy project for late NSCLC. The patients can be well tolerant.